Abiomed withdraws some Impella introducers due to possible sheath leakage
The manufacturer of Impella, Abiomed (Oscor), has issued a safety notice concerning selected 14 Fr and 23 Fr introducer models. A problem in the manufacturing process may lead to sheath leakage and increase the risk of bleeding at the vascular access site.

JAFAR AHMED · Unsplash License
- 0views
- 0likes and saves
- 0skips
In brief
- Abiomed (Oscor) has issued a safety notice concerning selected models of Impella 14 Fr and 23 Fr introducer sheaths.
- A production problem may cause the sheath to leak and increases the risk of bleeding at the vascular access site.
- The warning is addressed to medical staff; decisions about patient management are made by the treating physician.
What the notice concerns
The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products published a safety notice bearing number 2026-FA-0000143, issued by Abiomed (Oscor). It concerns certain models of the Abiomed Impella Introducer Kit sets in sizes 14 Fr and 23 Fr (Safety notice (2026-FA-0000143) from Abiomed (Oscor) concerning certain models of the Abiomed Impella Introducer Kit 14 Fr and 23 Fr, issued due to the possibility of introducer sheath leakage resulting from production process problems, increasing the risk of bleeding at the vascular access site – Office for Registration of Medicinal Products, Medical Devices and Biocidal Products).
What the problem is
The cause is the possibility of leakage from the introducer sheath. The defect results from problems in the production process. A leaking sheath increases the risk of bleeding at the vascular access site, that is, the place through which the device is introduced into a blood vessel.
Who it affects
The notice covers only the specified models of introducers. The warning is directed at medical staff working with these sets, namely interventional cardiology and cardiac surgery teams that use heart support systems. Patients who have already undergone the procedure do not need to take any action on their own. Decisions about further management are made by the treating physician.
What's next
The notice points to the need to pay attention to the vascular access site in patients in whom these introducers were used, and to respond quickly if signs of bleeding appear. Detailed recommendations for healthcare facilities are contained in the document available on the URPLWMiPB website.
The notice was published on 17 November 2026.
Sources
Discussion0
- No comments from this perspective yet. Be the first.